Graph AI Raises $3 Million to Automate Drug Safety with AI
- Graph AI secures $3 Million seed funding led by Bessemer Venture Partners.
- Startup uses AI to automate drug safety reporting and compliance.
- Plans to scale product, grow team, and expand adoption globally.
California based Graph AI, a healthtech startup using AI to automate drug safety monitoring, has raised $3 million in seed funding. The round was led by Bessemer Venture Partners and will help the company scale its platform, expand the engineering team, and drive adoption among global pharmaceutical firms.
Founded in 2024 by Raghav Parvataraju, Vijay Ponukumati, Mohan Konyala, and Ashutosh Bordekar, Graph AI aims to modernize pharmacovigilance, the process drugmakers use to detect and report adverse drug events. Traditionally a manual and time consuming task, it is now being transformed through AI powered automation.
Graph AI’s flagship product, Graph Safety, uses context aware AI to automate core pharmacovigilance tasks such as case processing, signal detection, and regulatory reporting, while still allowing human oversight for critical decisions. The platform reduces manual workload, speeds up processes by up to 90%, and cuts costs by 70%, according to the company.
Pharmaceutical companies are legally required to monitor side effects from clinical trials and post-market use. But current systems are often fragmented and slow. Graph AI aims to solve this with a seamless, AI native approach that blends compliance, context, and automation.The founders, said “We’re helping drugmakers shift from outdated systems to intelligent, scalable platforms”.
Also Read: Consuma AI Raises Rs 12 Crore to Transform Consumer Research
Bessemer’s Nithin Kaimal said, the investment reflects growing belief in 'intelligence arbitrage', replacing labor heavy services with smart, scalable tech.
Graph AI already works with enterprise clients and is building solutions that could support safety monitoring for over 7,000 marketed drugs.
